PE20001353A1 - Oximas e hidrazonas sustituidas como antagonistas de neuroquinina - Google Patents

Oximas e hidrazonas sustituidas como antagonistas de neuroquinina

Info

Publication number
PE20001353A1
PE20001353A1 PE1999001305A PE00130599A PE20001353A1 PE 20001353 A1 PE20001353 A1 PE 20001353A1 PE 1999001305 A PE1999001305 A PE 1999001305A PE 00130599 A PE00130599 A PE 00130599A PE 20001353 A1 PE20001353 A1 PE 20001353A1
Authority
PE
Peru
Prior art keywords
alkyl
cr6r7
heteroaryl
neuroquinin
hydrazones
Prior art date
Application number
PE1999001305A
Other languages
English (en)
Inventor
Gregory A Reichard
Dasong Wang
Neng-Yang Shih
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001353A1 publication Critical patent/PE20001353A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXIMAS E HIDRAZONAS DE FORMULA I, DONDE: a ES 0-3; b Y d SON 1-2; R ES H, ALQUILO C1-C6, OR6, F; A ES =N-OR1, =N-NR2R3; CUANDO d NO ES O, X ES UN ENLACE CO, O, NR9, SOe, NR6CO, CONR6, ENTRE OTROS; CUANDO d ES 0, X ES UN ENLACE, NR6; T ES H, R4-ARILO, R4-HETEROCICLOALQUILO, R4-HETEROARILO; Q ES R5-FENILO, R5-NAFTILO, R5-HETEROARILO; R1 ES H, ALQUILO C1-C6, -(CR6R7)n, G, G2, (CR6R7)p, ENTRE OTROS; R2 Y R3 SON H, ALQUILO C1-C6, -(CR6R7)n-G, G2 Y -S(O)eR13; R2 Y R3 JUNTO CON N FORMAN UN ANILLO DE 5-6 MIEMBROS; R4 Y R5 SON H, HALOGENO, OR6, OCOR6, CONR6R7, NR6R7, ALQUILO C1-C6, CF3, C2F5, COR6, CO2R6, CONR6R7, ENTRE OTROS; R6, R7, R8, R13, R14 SON H, ALQUILO C1-C6, HIDROXIALQUILO C2-C6, ALCOXI C1-C6-ALQUILO C1-C6; R9 ES R6 OR6; n Y p SON 1-6; G ES H, R4-ARILO, R4-HETEROCICLOALQUILO, R4-HETEROARILO, R4-CICLOALQUILO, CH2F, CF3, OR6, NR6R7, ENTRE OTROS; G2 ES R4-ARILO, R4-HETEROCICLOALQUILO, R4-HETEROARILO, R4-CICLOALQUILO, COR6, CO2R16, SO2NR6R7, ENTRE OTROS; e ES 0-2; CUANDO e ES 1-2, R13 Y R10a NO SON H. Z ES DE PREFERENICA UN GRUPO a, k ES 1-4; R26 ES H, ALQUILO C1-C6, (CR6R7)t-G, G2, ENTRE OTROS. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE NEUROQUININA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, TRASTORNOS DE LA PIEL, OFTALMOLOGICOS
PE1999001305A 1998-12-23 1999-12-21 Oximas e hidrazonas sustituidas como antagonistas de neuroquinina PE20001353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22031698A 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
PE20001353A1 true PE20001353A1 (es) 2000-12-07

Family

ID=22823070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001305A PE20001353A1 (es) 1998-12-23 1999-12-21 Oximas e hidrazonas sustituidas como antagonistas de neuroquinina

Country Status (14)

Country Link
EP (1) EP1144402B1 (es)
JP (2) JP4370059B2 (es)
CN (1) CN1414961A (es)
AR (1) AR021968A1 (es)
AT (1) ATE277035T1 (es)
AU (1) AU2474200A (es)
CA (1) CA2355886C (es)
CO (1) CO5160341A1 (es)
DE (1) DE69920516T2 (es)
ES (1) ES2226493T3 (es)
HK (1) HK1037182A1 (es)
PE (1) PE20001353A1 (es)
TW (1) TW533210B (es)
WO (1) WO2000039114A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001353A1 (es) * 1998-12-23 2000-12-07 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
IL158484A0 (en) 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
UA75425C2 (en) * 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
ES2327654T3 (es) * 2004-04-07 2009-11-02 Schering Corporation Antagonista de nk1 de anillo condensado.
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
AU2010204723A1 (en) 2009-01-14 2011-08-18 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
BR9814987A (pt) * 1997-11-21 2000-10-03 Schering Corp "oximas substituìdas como antagonistas da neurocinina"
PE20001353A1 (es) * 1998-12-23 2000-12-07 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina

Also Published As

Publication number Publication date
CA2355886A1 (en) 2000-07-06
AU2474200A (en) 2000-07-31
CA2355886C (en) 2006-10-31
TW533210B (en) 2003-05-21
EP1144402A2 (en) 2001-10-17
DE69920516T2 (de) 2005-12-01
WO2000039114A3 (en) 2001-11-29
EP1144402B1 (en) 2004-09-22
CO5160341A1 (es) 2002-05-30
JP2006298939A (ja) 2006-11-02
JP4370059B2 (ja) 2009-11-25
WO2000039114A2 (en) 2000-07-06
JP2002533451A (ja) 2002-10-08
ES2226493T3 (es) 2005-03-16
ATE277035T1 (de) 2004-10-15
CN1414961A (zh) 2003-04-30
DE69920516D1 (de) 2004-10-28
EP1144402A3 (en) 2002-09-11
HK1037182A1 (en) 2002-02-01
AR021968A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
PE20001353A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
PE20221264A1 (es) Inhibidores de egfr
PE106499A1 (es) Antagonistas del receptor ccr-3
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
AR019626A1 (es) Antagonistas receptores y5 de neuropeptidos.
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
PE20020332A1 (es) Derivados de 4-fenil-piridina como antagonistas de receptores de neuroquinina nk-1
PE20020221A1 (es) CARBAMATOS AZABICICLICOS COMO AGONISTAS DEL RECEPTOR DE ACETILCOLINA NICOTINICO alfa 7
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE109598A1 (es) Pirrolcarboxamidas condensadas, utiles como ligandos de receptores cerebrales gaba
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20030809A1 (es) Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch)
AR053566A1 (es) Compuestos espiriciclicos antagonistas de los receptores de trombina
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
HUP0500096A2 (hu) Kondenzált heterociklusos vegyületek és analógjaik mint a nukleáris hormon receptor funkció modulátorai, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20011084A1 (es) Derivados de quinolina como antagonistas alfa-2
PE20010575A1 (es) Derivados de indol y su uso como ligandos del receptor 5ht2
JPH06511251A (ja) ヒスタミンｈ↓３アゴニスト／アンタゴニストとしてのイミダゾリル−アルキル−ピペラジンおよび−ジアゼピン誘導体
PE20040757A1 (es) Derivados de benzoxazina
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
FI893634A (fi) Menetelmä valmistaa terapeuttisesti aktiivisia mono- tai disubstituoituja (imidatsol-4-yyli)metyylipyrido/4,3-b/indol- ja atsepino/4,3-b/indol-1-oneja
PE133799A1 (es) Antagonistas del receptor de trombina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed